Search results
How to Safely Discontinue Multiple Myeloma Maintenance Care
Medscape· 4 days agoNew research suggested that the key to safely discontinuing multiple myeloma maintenance therapy is...
'General Hospital' star John J York returns to work after 'aggressive' cancer treatment
Fox News· 2 hours ago"General Hospital" star John J. York got emotional while recounting his long cancer battle. York,...
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma
MedPage Today· 4 days agoMedPage Today brought together three expert leaders in the field: Moderator...
CARsgen’s CAR T MM therapy shows early signs of efficacy in Phase I trial
Clinical Trials Arena via Yahoo Finance· 1 day agoShanghai based-biotech company CARsgen Therapeutics has announced that its CAR T cell candidate...
Head to Head Survey: Evaxion Biotech A/S (NASDAQ:EVAX) and Halozyme Therapeutics (NASDAQ:HALO)
ETF DAILY NEWS· 5 days agoHalozyme Therapeutics (NASDAQ:HALO – Get Free Report) and Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the ...
Legend Biotech (NASDAQ:LEGN) Given Overweight Rating at Piper Sandler
ETF DAILY NEWS· 11 hours agoPiper Sandler reaffirmed their overweight rating on shares of Legend Biotech (NASDAQ:LEGN – Free Report) in a report released on Monday, Benzinga reports. They currently have a $90.00 price ...
Fate Therapeutics (NASDAQ:FATE) Upgraded to Overweight by Piper Sandler
ETF DAILY NEWS· 12 hours agoPiper Sandler upgraded shares of Fate Therapeutics (NASDAQ:FATE – Free Report) from a neutral rating to an overweight rating in a report published on Monday, MarketBeat.com reports. They currently ...
Legend Biotech (NASDAQ:LEGN) Receives New Coverage from Analysts at Truist Financial
ETF DAILY NEWS· 12 hours agoTruist Financial assumed coverage on shares of Legend Biotech (NASDAQ:LEGN – Free Report) in a research report sent to investors on Monday morning, MarketBeat reports. Several other equities ...
BioLineRx Ltd. to Post Q2 2024 Earnings of ($0.01) Per Share, Zacks Small Cap Forecasts...
ETF DAILY NEWS· 5 days agoBioLineRx Ltd. (NASDAQ:BLRX – Free Report) – Analysts at Zacks Small Cap issued their Q2 2024 earnings per share (EPS) estimates for BioLineRx in a research note issued on Monday, June 10th.
Oppenheimer Lowers Cellectis (NASDAQ:CLLS) Price Target to $10.00
ETF DAILY NEWS· 4 days agoCellectis (NASDAQ:CLLS – Get Free Report) had its target price dropped by Oppenheimer from $11.00 to $10.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently ...